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Patient, doctor, disease, and informed
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Il paziente, il medico, la malattia e il consenso
informato  
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Lung cancer is the 10th ranking cause of death in the
world: its incidence has reached a steady state in
the male gender while it is still increasing in fe-
males. Even if data are now available on lung can-
cer screening with low-dose spiral computerized
tomography (CT), still today the diagnosis is often
late, due to underestimation and late appearance of
specific symptoms. Hence, in the great majority of
cases (stages IIIB and IV) the only possible option is
a definitive chemotherapy with a platin doublet,
alone or with bevacizumab, or other target drugs.
Unfortunately, the results are not satisfying, either
for overall survival or for progression free survival.
So, performing new clinical trials is essential.
Taking into account the prognosis of locally ad-
vanced or metastatic lung cancer, the utility of
chemotherapy is discussed more often with the pa-
tient’s relatives than with the patient him/herself.
But survival and quality of life (QoL) are significant-
ly better in patients treated with chemotherapy than
in those who receive the best supportive care but
not chemotherapy.
In this respect it has been demonstrated that the pa-
tient is more agreeable to chemotherapy than are
the relatives and even the doctor, if the expected re-
sults are in terms of survival or quality of life [1]:
• 57% of patients opt for chemotherapy if the one-
year-survival is at least 10% 
• 68% of patients opt for chemotherapy if the QoL
is ameliorated
• the majority of patients opt for chemotherapy if a
median survival of at least 4.5 months is expect-
ed.
So, a real informed consent is of paramount impor-
tance in order to obtain the patient’s cooperation
for the therapeutic plan. The informed participation
of the patient – in the sense of understanding the dis-
ease, its therapy and the interaction between the two
- is necessary for the patient to be able to deal with a
critical period of his/her life. This task is even more
important in the case of enrolment in clinical trials.
The study by Zaric et al. in this issue [2] carried out
a survey on the perception of lung cancer patients
undergoing experimental treatments. The authors
argue that “the patients participating in clinical tri-
als contribute not only to their own and future pa-
tients’ treatment benefits, but also to the benefits of
medicine and the science itself” and they ask the
question: “physicians are aware of this fact, but are
the patients aware of the same fact, too?”.
In this respect, 59 patients with advanced lung can-
cer, previously treated and enrolled in a clinical
therapeutic trial, filled in a questionnaire with 20
items. The patients were asked about their know -
ledge of their own disease (type, stage) and the kind
of therapy (previously and currently received),
about the information received on the trial results,
and about the utility of the experimental trial itself
and the quality of treatment.
All the patients were familiar with the nature of
their disease, and the majority of them knew their
lung cancer stage. A significant number of patients
knew what kind of chemotherapy they received.
Almost all patients knew that they were participat-
ing in a clinical trial and they believed that the
chemotherapy given in the clinical trial would give
them a better chance for survival.
The fact that 8.5% of the patients (more often the
less educated ones) did not read the entire informed
consent form (ICF) is an alarming finding, because
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the ICFs provide more detailed information about
the trial than an investigator can give during the in-
terview with a patient. This suggests that doctors
should pay more attention when they provide infor-
mation to less educated patients. Giving clear infor-
mation, maintaining the patient's hope for the fu-
ture, permits to obtain the confidence and the col-
laboration of the patient. 
Some practical suggestions for physicians that can
be derived are:
• When informing the patient take into account
their educational level and do not use only the in-
formed consent, in particular in the presence of
less educated patients.
• Do not hide from the patients their real condition.
• Do not inform only the relatives, but make sure
also the patients are informed.
The results of the study by Zaric et al. strengthen the
fact that an honest attitude ameliorates the relation-
ship between patients and doctor, providing the pa-
tient with the knowledge to understand their dis-
ease, its actual state, the type and purpose of the
treatment, and helping them to cope with a very dif-
ficult period of their life.
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